{
    "clinical_study": {
        "@rank": "102644", 
        "arm_group": {
            "arm_group_label": "CLD from HIS-EX-408", 
            "description": "Chronic liver disease subjects from previous Exalenz trial \"HIS-EX-408\""
        }, 
        "brief_summary": {
            "textblock": "The objectives of this study are:\n\n        -  To evaluate the ability of the Methacetin Breath Test  (MBT) to detect hepatic\n           decompensation events\n\n        -  To evaluate the relationship between liver Biopsy and clinical outcome and show that\n           the MBT has a better predictive ability of clinical outcome than liver biopsy.\n\n        -  To evaluate the ability of the MBT to predict each of the individual liver related\n           complications."
        }, 
        "brief_title": "Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Liver Disease", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "Exalenz has previously gathered information in a previous study on patients with chronic\n      liver disease including the methacetin breath test. Several years later, the company wishes\n      to investigate this group of subjects and see retrospectively if the breath test was a\n      predictor of complications related to their liver disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All subjects that aere enrolled in the previous Exalenz trial HIS-EX-408\n\n        Exclusion Criteria:\n\n        None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Chronic liver disease subjects from previous Exalenz trial \"HIS-EX-408\""
            }
        }, 
        "enrollment": {
            "#text": "414", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084160", 
            "org_study_id": "HIS-FU-EX-1213"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel"
                }, 
                "name": "Hadassah Medical Origanzation"
            }, 
            "status": "Active, not recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation; a Retrospective Analysis", 
        "overall_contact": {
            "email": "avrahamh@exalenz.com", 
            "last_name": "Avraham D Hershkowitz, MSc", 
            "phone": "+972-8-9737513"
        }, 
        "overall_official": {
            "affiliation": "Hadassah Medical Organization", 
            "last_name": "Meir Mizrachi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hepatic decompensation is defined as the occurrence of at least one of the following events in the time frame between the last 13C Methacetin Breath Test (MBT) to the time of data collection:\nDeath (liver related)\nTransplantation (cadaveric and living donors)\nAscites\nHE (Hepatic Encephalopathy)\nNewly diagnosed varices or variceal bleeding\nSBP (spontaneous bacterial peritonitis)\nHRS (Hepatorenal syndrome)\nHCC (hepatocellular carcinoma)\nIncrease in CTP (Child Turcotte Pugh) Score by 3 points\nIncrease in MELD score by 5 points", 
            "measure": "Hepatic decompensation event", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084160"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Exalenz Bioscience LTD.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Exalenz Bioscience LTD.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}